Software/Gaming/IT

Capital Region is Active in AI R&D

IBM’s announcement last month of its new Telum processor developed at its new research center at the Albany Nanoplex Complex is just one example of how the Capital Region is making its mark in artificial intelligence (AI) R&D. Local institutions are participating in major AI research projects funded by the

Entrepreneurship

Capital Region is a top contender for venture capital investment among mid-sized Northeast metros

While venture capital tends to concentrate in large metros such as New York City and Boston, businesses in the Albany metro area are faring better at attracting VC investment better than those in their mid-sized counterparts in the Northeast, according to a Center for Economic Growth analysis of U.S. Census

Economic Analysis, Entrepreneurship, Regional/County Profiles

Capital Region Business Formation Increased through Pandemic

Business formation continued in the Capital Region throughout 2020 and despite the pandemic. Last year, 9,456 applications to form a business were filed in the eight-county Capital Region, up by 295 (3.2 percent) from the previous year, according to a Center for Economic Growth (CEG) analysis of new U.S. Census

Biotechnology/Life Sciences/Pharmaceuticals

The Capital Region Has This Many FDA-Registered Medical Device Establishments

The Capital Region has more than 20 U.S. Food and Drug Administration (FDA)-registered establishments involved in the manufacturing and preparation of more than 1,300 medical devices, according to a Center for Economic Growth (CEG) analysis of the FDA data. Establishment Types As of March 2021, the eight-county region had 25

General, Research & Development

Businesses Spent This Much More on R&D at Capital Region Colleges and Universities

R&D funded by businesses up 51% at RPI, 39% at SUNY Poly Increased business funding helped fuel a 6.9 percent increase in research and development spending at Capital Region colleges and universities in 2019, according to a Center for Economic Growth (CEG) analysis of new data from that National Center

General, Nanotechnology

These Semiconductor Startups Drove the Capital Region to an NSF Seed Funding Record

The federal agency chiefly responsible for driving innovation and commercialization in the private marketplace awarded a record sum of seed funding to Capital Region startups in fiscal 2020, with advanced-stage semiconductor R&D boosting the award total, according to a Center for Economic Growth (CEG) analysis of preliminary data from the

Research & Development

Capital Region’s Academic R&D Footprint Spans 1.5M Square Feet

Skidmore set to double R&D space with CIS, Ualbany preps ETEC for June opening The Capital Region’s academic research and development footprint spanned 1.5 million square feet in 2019 and promises to stretch farther with several building projects in the pipeline. Most notably among those developments are the University at

Research & Development

Capital Region Businesses Spent $1B+ on R&D in 2018

Capital Region businesses continue to spend more than $1 billion on research and development, making it one of only 51 metros nationwide to surpass that threshold, according to a Center for Economic Growth (CEG) analysis of new data from the National Center for Science and Engineering Statistics (NCSES). R&D spending

Biotechnology/Life Sciences/Pharmaceuticals, General, News, Research & Development

Capital Region Nets $81.5M in NIH Awards – Most in 12 Years

FOR IMMEDIATE RELEASE GE Research receives record amount of NIH awards, Union prof’s neuro-exergame in clinical trials   ALBANY, NEW YORK – In fiscal 2020, the Capital Region’s Life Sciences Cluster received its greatest amount of National Institutes of Health (NIH) awards in 12 years, when adjusting for inflation. The

Biotechnology/Life Sciences/Pharmaceuticals, Manufacturing

Capital Region Has 40 FDA-Registered Drug Establishments, including Most API MFGs in NYS

FOR IMMEDIATE RELEASE Region’s biopharma industry gets new training center in January with ACPHS’s CBET ALBANY, NEW YORK – While Regeneron Pharmaceuticals’ East Greenbush plant attracts global interest for making its COVID-19 antibody cocktail consisting of two active pharmaceutical ingredients (APIs), there are several other facilities in the Capital Region

Funding Partners